Mussel Oil And Powder - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The mussel oil and Powder Market reached USD 0.74 billion in 2025, is valued at USD 0.81 billion in 2026, and will expand to USD 1.29 billion by 2031, registering a 9.60% CAGR during the forecast period. This report is Segmented by Form (Mussel Oil, Mussel Powder), Application (Dietary Supplements, Animal Nutrition, Foods and Beverages, and More), and Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa). The Market Forecasts are Provided in Terms of Value (USD) and Volume (Tons).

Global Mussel Oil And Powder Market Trends and Insights

Rising Consumer Awareness of Anti-Inflammatory and Joint Health Benefits of Mussel-Derived Ingredients

The clinical validation of green-lipped mussel extract for osteoarthritis management has shifted the ingredient from niche supplement to evidence-based intervention. A 2024 systematic review published in Marine Drugs confirmed that mussel oil's unique omega-3 fatty acid profile, particularly eicosatetraenoic acid (ETA), inhibits both COX-2 and 5-LOX pathways, offering dual anti-inflammatory action that synthetic NSAIDs cannot replicate without adverse gastrointestinal effects. This mechanistic differentiation appeals to aging populations in Japan and Germany, where healthcare systems incentivize non-pharmaceutical pain management. The FDA's revised guidelines on dietary supplement health claims and the removal of molluscan shellfish from major allergen categories have increased market confidence by providing clear communication guidelines and reducing allergy-related concerns . The ingredient's positioning as a marine alternative to glucosamine-chondroitin combinations is gaining traction among orthopedic practitioners who prescribe it as adjunct therapy, creating a physician-driven demand channel that bypasses traditional retail supplement distribution.

Expanding Demand for Omega-3-Rich Marine Ingredients in Functional Nutrition

Omega-3 phospholipids derived from mussel oil offer materially higher bioavailability than the triglyceride forms found in conventional fish oil, allowing formulators to achieve equivalent physiological outcomes at lower inclusion rates. Evidence from the Liggins Institute indicates that mussel oil phospholipids deliver approximately 1.7 times greater plasma EPA incorporation versus fish oil on a dose-equivalent basis. This enables manufacturers to meet nutritional label claims with reduced ingredient loadings, improving formulation efficiency and supporting margin optimization, particularly in cost-sensitive formats such as protein bars and ready-to-drink beverages. Rising disposable incomes across Asia-Pacific, especially in China and India, are accelerating demand for premium functional foods that deliver clinically meaningful omega-3 levels without the sensory drawbacks of traditional marine oils. Mussel oil’s relatively neutral taste profile provides a competitive advantage in this context, aligning with consumer preferences for both efficacy and palatability.

Elevated Production and Processing Costs Impacting Price Competitiveness

Production costs remain a critical constraint in the mussel oil and powder industry, driven by capital-intensive extraction technologies and complex processing requirements. The adoption of supercritical CO₂ extraction, while essential for preserving bioactive compounds and ensuring product stability, requires significant upfront investment, typically ranging from USD 2 million to USD 5 million, along with highly specialized technical expertise. This elevates both capital expenditure (CAPEX) and ongoing operational expenditure (OPEX). Beyond extraction, downstream processes such as de-fatting, freeze-drying, and purification are energy-intensive and demand advanced infrastructure, further increasing unit production costs. Labor also represents a structural cost disadvantage. Logistics add another layer of complexity and cost. Mussel oil is highly susceptible to oxidation, necessitating strict cold-chain management across storage and transportation. Temperature-controlled shipping significantly increases freight expenses, often doubling costs compared to shelf-stable alternatives, while also introducing operational risks in long-distance distribution.

Other drivers and restraints analyzed in the detailed report include:

• Accelerating Shift Toward Marine-Based, Clean-Label Health Solutions
• Advancements and Innovation in Extraction and Processing Technologies
• Increasing Adoption of Plant-Based and Vegan Diets Constraining Demand for Mussel-Derived Products

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Mussel oil's 72.80% revenue share in 2025 stems from its phospholipid-bound omega-3 structure, which bypasses hepatic metabolism and delivers EPA and DHA directly to cell membranes, a pharmacokinetic advantage that clinical formulators prioritize for anti-inflammatory protocols. The segment's dominance reflects the nutraceutical industry's preference for liquid softgel formats, which command higher retail price points than powder-filled capsules.

Mussel powder, however, is forecast to expand at 11.70% CAGR through 2031, driven by its integration into pet nutrition and functional food applications where oil's liquid form presents formulation challenges. Powder's lower moisture content extends shelf life to 24 months versus oil's 18-month window, reducing inventory risk for distributors operating in tropical climates. Emerging applications for mussel powder include its use as a natural flavor enhancer in savory snacks, where its umami profile, derived from free amino acids and nucleotides, replaces monosodium glutamate in clean-label formulations.

Complete Report Scope:

• By Form
  • Mussel Oil
  • Mussel Powder
• By Application
  • Dietary Supplements
  • Animal Nutrition
  • Food and Beverages
  • Pharmaceuticals/ Biopharmaceuticals
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • France
    • Netherlands
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East and Africa

Geography Analysis

Asia-Pacific's 45.10% market share in 2025 reflects Japan's aging society, where 29% of the population exceeded 65 years in 2025, and the country's cultural acceptance of marine-based health products. Japan's Ministry of Health, Labour and Welfare recognizes mussel extract under its Foods with Function Claims (FFC) framework, enabling manufacturers to make joint health claims without pre-market approval, a regulatory pathway that accelerates product launches. China's market is expanding as urban consumers adopt preventive health behaviors, with mussel oil positioned as a premium alternative to fish oil in tier-1 cities like Shanghai and Beijing. Australia's domestic consumption remains modest, but the country serves as a re-export hub for New Zealand mussel products entering Southeast Asian markets.

South America is forecast to grow at 10.50% CAGR through 2031, driven by Chile's aquaculture expansion and Brazil's burgeoning wellness economy. Chile produced 412,000 metric tons of mussels in 2024, positioning the country as the world's second-largest supplier after China, yet most output is exported as frozen meat rather than processed into oil or powder .

North America and Europe together accounted for approximately 35% of global revenue in 2025, with the United States leading due to its established dietary supplement market and high consumer spending on preventive health. Europe's market is shaped by EFSA's stringent health claim regulations, which require robust clinical evidence before permitting structure-function statements on labels. The Middle East and Africa represent emerging opportunities, with South Africa's urban centers showing early adoption of marine nutraceuticals, though distribution infrastructure and consumer education remain limiting factors.

List of Companies Covered in this Report:

• MacLab (NZ) Limited
• Aroma NZ Limited
• Waitaki Bio Limited
• Sanford Limited
• Pharmalink International Limited (Lyprinol)
• Gencor Pacific Limited
• BioMarin NZ Limited
• MarinePhos NZ Limited
• The Scoular Company
• Shaanxi Yuantai Biological Technology Co., Ltd.
• Green Jeeva, LLC
• Shaanxi Pioneer Biotech Co., Ltd.
• ICEPAW GmbH
• GreenHerb Biological Technology Co., Ltd.
• Runherb, Inc.
• Trafa Pharmaceutical, Inc.
• NZ Superfood & Co. Limited
• NutriCargo, LLC
• RMF Nutraceuticals, LLC
• Mocca & Co. Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support